PTK6: An emerging biomarker for prognosis and immunotherapeutic response in clear cell renal carcinoma (KIRC)

• DOI: 10.1016/j.heliyon.2024.e29001
• Publication Date: 2024-03-29T03:14:48Z
• Authors: Lizhen Lin; Siming Gong; Chao Deng; Guanxiong Zhang; Jing Wu
• Keywords: Kidney cancer

Kidney renal clear cell carcinoma (KIRC), one of the most prevalent form kidney carcinoma, is highly aggressive cancer known for significant immune infiltration and high mortality rates. The absence sensitivity to traditional therapy has spurred search new treatments. Protein Tyrosine Kinase 6 (PTK6) implicated in promoting growth, spread, metastasis. Our review Cancer Genome Atlas database revealed PTK6 overexpression KIRC, though its specific role this type was unclear. We investigated PTK6's cancer-promoting roles KIRC using confirmed our findings with patient-derived tissues. analysis showed that elevated expression linked worse outcomes higher levels infiltration. It also correlates positively neo-antigens (NEO) DNA ploidy changes KIRC. This research delves into development, suggesting as a possible biomarker prognosis treatment